Cara Therapeutics Stock News

Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri Holdings Limited (NYSE:

Shares of Cara Therapeutics (CARA) are down 8% in after-hours trading after the companys Q4 2021 results missed on the top and bottom lines.

Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics press release (NASDAQ:CARA): GAAP EPS of -$0.63 misses by $0.11.Revenue of $0.82M (-99.3% Y/Y) misses by $0.43M.Shares -5.5%.

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed

Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q4 2021 Results - Earnings Call Transcript

Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.

Cara Therapeutics (NASDAQ:CARA) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is -$0.48 (-130.2% Y/Y) and the…

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics (CARA) said a committee of the European Medicines Agency’s ((EMA)) recommended the approval of Kapruvia (difelikefalin)…

ST. GALLEN, Switzerland and STAMFORD, Conn., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the

ST. GALLEN, Switzerland and STAMFORD, Conn., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia ® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. The CHMP opinion is the basis for the European Commission’s final decision regarding marketing authorization for Kapruvia ® . If approved, Kapruvia ® will be the first therapy available in Europe for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients.

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives